Invention Grant
- Patent Title: Universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (MSI) cancers
-
Application No.: US16626458Application Date: 2018-07-12
-
Publication No.: US11578109B2Publication Date: 2023-02-14
- Inventor: Alfredo Nicosia , Elisa Scarselli , Guido Leoni , Armin Lahm
- Applicant: NOUSCOM AG
- Applicant Address: CH Basel
- Assignee: NOUSCOM AG
- Current Assignee: NOUSCOM AG
- Current Assignee Address: CH Basel
- Agency: McDonnell Boehnen Hulbert & Berghoff, LLP
- Priority: EP17181026 20170712
- International Application: PCT/EP2018/069032 WO 20180712
- International Announcement: WO2019/012082 WO 20190117
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61P35/00 ; A61K38/16 ; A61K38/10 ; A61K38/08 ; C07K5/00 ; C07K7/00 ; C07K16/00 ; C07K17/00 ; A61K38/04 ; C07K14/47 ; G16B20/00 ; A61K39/00 ; C12N15/00

Abstract:
This invention relates to a method of selecting a collection of frame-shift peptides (CFSPs) to produce a universal cancer vaccine peptide collection (CVP) for prophylaxis and treatment of patients with hereditary and sporadic micro-satellite instability (MSI) tumors. This invention relates as well to a method of producing a CVP by selecting a subset of frame-shift peptides (FSPs) from the CFSP and optionally modifying the FSP's amino acid (aa) sequence to generate modified FSPs (mFSPs). The invention further relates to nucleic acid collections encoding a CVP of FSPs and/or mFSPs in one or more vaccine vectors that can be used also simultaneously. These CVPs, nucleic acids and vectors are used for the prophylaxis or treatment of MSI cancers.
Public/Granted literature
Information query
IPC分类: